Sercan Çayırlı
Research Subjects
Sercan Çayırlı has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
- Ahmet Dal
Faculty of Medicine, Department of Cardiology, Izmir University of Economics, Izmir, Turkey
3 shared publications - Arda Güler
Department of Cardiology, University of Health Sciences, Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Center, Training and Research Hospital, İstanbul, Türkiye
3 shared publications - Aslan Erdoğan
Cardiology Department Basaksehir Cam Sakura City Hospital G‐434 Cd. Istanbul Türkiye
3 shared publications - Bektas Murat
Department of Cardiology, Eskisehir City Hospital
3 shared publications - Bengisu Keskin Meriç
Department of Cardiology, Babaeski State Hospital, Kırklareli, Turkey
3 shared publications - Cihan Altin
Department of Cardiology, Faculty of Medicine Izmir University of Economics Izmir Türkiye
3 shared publications
Latest Publications
- Open Access
- 8 June 2026
- Published by Kosuyolu Heart Journal, Health Sciences University in Kosuyolu Heart Journal
- Vol. 29 (2) , 114-120
Comparison of Bleeding Risk Scores in Atrial Fibrillation Patients on Direct-Acting Oral Anticoagulants: A Real-Life Study
Objective: Hemorrhagic complications continue to be a major clinical challenge among individuals with atrial fibrillation (AF) receiving direct-acting oral anticoagulants (DOACs). This research sought to evaluate and contrast the accuracy of various risk assessment models in forecasting bleeding incidents within this specific patient cohort. Methods: We enrolled 447 subjects diagnosed with AF who were prescribed DOAC therapy (including apixaban, dabigatran, edoxaban, or rivaroxaban). By retrospectively reviewing institutional electronic health records, we computed the ORBIT, ATRIA, and HEMORR 2 HAGES risk indices for each participant. The main outcome measures were defined as the occurrence of clinically relevant minor or major hemorrhages. Consequently, we analyzed how accurately these scoring systems could foresee the specified endpoints. Results: The cohort’s average age stood at 75.6±10.1 years, comprising predominantly women (62.2%). During a 12-month observation period, 6.7% of the participants (n=30) encountered one or more major hemorrhagic events. When forecasting severe bleeding, the ATRIA, ORBIT, and HEMORR 2 HAGES frameworks exhibited comparable predictive accuracies without any statistically notable variations. Upon conducting a multivariate logistic regression, independent variables linked to a heightened likelihood of bleeding encompassed prior hemorrhagic episodes (odds ratio [OR]: 3.101, p=0.019) and the presence of heart failure (OR: 2.028, p=0.009). In addition, anemia emerged as a significant factor (OR: 0.366, p=0.049), alongside elevated evaluations in both the HEMORR 2 HAGES (OR: 1.535, p=0.006) and ORBIT (OR: 1.849, pConclusion: Both the ORBIT and HEMORR 2 HAGES models proved to be valuable independent indicators for future hemorrhagic complications. Integrating these tools into routine cardiovascular care can optimize therapeutic strategies and enhance the overall safety of AF patients on anticoagulation.
- 8 June 2026
- Published by Kosuyolu Heart Journal, Health Sciences University in Kosuyolu Heart Journal
- Vol. 29 (2) , 114-120
Open AccessComparison of Bleeding Risk Scores in Atrial Fibrillation Patients on Direct-Acting Oral Anticoagulants: A Real-Life Study
Objective: Hemorrhagic complications continue to be a major clinical challenge among individuals with atrial fibrillation (AF) receiving direct-acting oral anticoagulants (DOACs). This research sought to evaluate and contrast the accuracy of various risk assessment models in forecasting bleeding incidents within this specific patient cohort. Methods: We enrolled 447 subjects diagnosed with AF who were prescribed DOAC therapy (including apixaban, dabigatran, edoxaban, or rivaroxaban). By retrospectively reviewing institutional electronic health records, we computed the ORBIT, ATRIA, and HEMORR 2 HAGES risk indices for each participant. The main outcome measures were defined as the occurrence of clinically relevant minor or major hemorrhages. Consequently, we analyzed how accurately these scoring systems could foresee the specified endpoints. Results: The cohort’s average age stood at 75.6±10.1 years, comprising predominantly women (62.2%). During a 12-month observation period, 6.7% of the participants (n=30) encountered one or more major hemorrhagic events. When forecasting severe bleeding, the ATRIA, ORBIT, and HEMORR 2 HAGES frameworks exhibited comparable predictive accuracies without any statistically notable variations. Upon conducting a multivariate logistic regression, independent variables linked to a heightened likelihood of bleeding encompassed prior hemorrhagic episodes (odds ratio [OR]: 3.101, p=0.019) and the presence of heart failure (OR: 2.028, p=0.009). In addition, anemia emerged as a significant factor (OR: 0.366, p=0.049), alongside elevated evaluations in both the HEMORR 2 HAGES (OR: 1.535, p=0.006) and ORBIT (OR: 1.849, pConclusion: Both the ORBIT and HEMORR 2 HAGES models proved to be valuable independent indicators for future hemorrhagic complications. Integrating these tools into routine cardiovascular care can optimize therapeutic strategies and enhance the overall safety of AF patients on anticoagulation.
- Open Access
- 27 January 2025
- Published by Wiley in Clinical Cardiology
- Vol. 48 (1) , e70088
Incidence and Predictors of Clinical Outcomes in Real‐Life Patients With Atrial Fibrillation Treated With Oral Factor Xa Inhibitors: The Follow‐Up Results of the ANATOLIA‐AF Study
Objective: The main objective of this study is to determine the incidence and predictors of clinical outcomes in patients with AF treated with factor Xa inhibitors in a real‐world setting.Methods: The present study was a multicentre and observational study that included patients with AF who were treated with factor Xa inhibitors. The primary outcome was the composite of ischemic stroke, TIA, systemic embolism, major bleeding, and all‐cause mortality.Results: A total of 1162 patients from 26 cardiology centers were included in this study, with a median age of 72 years. During the median 12‐month follow‐up period, the primary outcome occurred in 195 patients (16.8%). Treatment with rivaroxaban compared with apixaban and edoxaban showed a lower rate of ischemic stroke, TIA, and/or systemic embolism (2.2% vs. 4.7% vs. 6.5%, respectively, p = 0.014). The major bleeding rate was similar between all three factor Xa inhibitors. The all‐cause mortality rate in the rivaroxaban group was lower compared with the apixaban and edoxaban groups (9.8% vs. 15.1% vs. 12.4%, respectively, p = 0.042). Overall, the frequency of primary outcome was 13.8%, 19.6%, and 20.6% for patients treated with rivaroxaban, apixaban, and edoxaban, respectively (p = 0.019). Older age, male sex, low body weight, high bleeding risk, heart failure, hypertension, liver failure, and treatment with apixaban 2.5 mg b.i.d. were independently associated with the development of primary outcome.Conclusion: The follow‐up data from the ANATOLIA‐AF study provides detailed data about the incidence and independent predictors of adverse clinical outcomes in patients with AF treated with factor Xa inhibitor treatment.
- 27 January 2025
- Published by Wiley in Clinical Cardiology
- Vol. 48 (1) , e70088
Open AccessIncidence and Predictors of Clinical Outcomes in Real‐Life Patients With Atrial Fibrillation Treated With Oral Factor Xa Inhibitors: The Follow‐Up Results of the ANATOLIA‐AF Study
Objective: The main objective of this study is to determine the incidence and predictors of clinical outcomes in patients with AF treated with factor Xa inhibitors in a real‐world setting.Methods: The present study was a multicentre and observational study that included patients with AF who were treated with factor Xa inhibitors. The primary outcome was the composite of ischemic stroke, TIA, systemic embolism, major bleeding, and all‐cause mortality.Results: A total of 1162 patients from 26 cardiology centers were included in this study, with a median age of 72 years. During the median 12‐month follow‐up period, the primary outcome occurred in 195 patients (16.8%). Treatment with rivaroxaban compared with apixaban and edoxaban showed a lower rate of ischemic stroke, TIA, and/or systemic embolism (2.2% vs. 4.7% vs. 6.5%, respectively, p = 0.014). The major bleeding rate was similar between all three factor Xa inhibitors. The all‐cause mortality rate in the rivaroxaban group was lower compared with the apixaban and edoxaban groups (9.8% vs. 15.1% vs. 12.4%, respectively, p = 0.042). Overall, the frequency of primary outcome was 13.8%, 19.6%, and 20.6% for patients treated with rivaroxaban, apixaban, and edoxaban, respectively (p = 0.019). Older age, male sex, low body weight, high bleeding risk, heart failure, hypertension, liver failure, and treatment with apixaban 2.5 mg b.i.d. were independently associated with the development of primary outcome.Conclusion: The follow‐up data from the ANATOLIA‐AF study provides detailed data about the incidence and independent predictors of adverse clinical outcomes in patients with AF treated with factor Xa inhibitor treatment.
- Open Access
- 23 September 2023
- Published by Medical Journal of Suleyman Demirel University in SDÜ Tıp Fakültesi Dergisi
- Vol. 30 (3) , 388-395
ST SEGMENT YÜKSELMESİZ MİYOKART ENFARKTÜS HASTALARINDA SİSTEMİK İMMÜN ENFLAMASYON İNDEKSİ VE MORTALİTE İLİŞKİSİ
Aim of the study Acute coronary syndrome (ACS) is a disease associated with high mortality and morbidity. It is essential to identify high-risk patients during hospitalization and to implement early revascularization strategies if necessary. There is a clear need for a simple, effective and cost-effective index for rapid identification of these patients in clinical practice. The aim of this study was to investigate the clinical significance of the systemic immune inflammation index (SII) in non-ST-segment elevation myocardial infarction (NSTEMI), a subgroup of ACS, and to evaluate its association with mortality. Materials and methods Patients who underwent coronary angiography at the Coronary Angiography Unit of Aydın Adnan Menderes University Faculty of Medicine Research and Training Hospital between January and December 2022 were retrospectively reviewed. Individuals with a diagnosis of NSTEMI were included as group I, and individuals with normal coronary arteries during coronary angiography were included as group II (control group). Clinical variables and calculated SII values of the groups were recorded. The role of SII in predicting all-cause mortality and its effect on expected survival were evaluated. Results The median value of the SII index was significantly higher in the NSTEMI group (group I) than in the control group (group II) (p<0.001). The mean neutrophil and SII index values of the mortality group were significantly higher than those of the survival group (p=0.002 and p=0.019, respectively). Multivariate logistic regression showed that the presence of NSTEMI (odds ratio [OR]: 9.891; 95% CI: 2.096-46.671, p609.98 and 79.3% for group I patients with SII <609.98, but the difference was not statistically significant (p=0.426). Conclusion Although the SII index has a role in predicting all-cause mortality in patients with NSTEMI, it is not useful in predicting survival. Amaç: AKS mortalitesi ve morbiditesi yüksek bir sendromdur. Yüksek riskli hastaların hastane yatışı esnasında belirlenmesi ve gerekli durumlarda erken revaskülarizasyon stratejilerinin uygulanması hastalarda hayati önem arz etmektedir. Klinik pratikte bu hastaların hızlıca belirlenmesine yönelik basit, etkili, maliyeti ucuz bir indeks ihtiyacı olduğu aşikardır. Tüm bu nedenlerden dolayı bu çalışmada tarafımızca SII’nın, AKS alt grubu olan NSTEMI geçiren hastalarda mortaliteyi ön görmedeki yerinin araştırılması amaçlanmıştır. Gereç ve Yöntem: 01.01.2022-31.12.2022 tarihleri arasından Aydın Adnan Menderes Üniversitesi Tıp Fakültesi Uygulama ve Araştırma Hastanesi koroner anjiyografi ünitesinde koroner anjiyografi işlemi uygulanan hastalar geçmişe dönük olarak tarandı. St segment yükselmesiz miyokart enfarktüsü geçiren hastalarda ve normal koroner arterler saptanan hastalarda SII [(nötrofil x platelet) / lenfosit] hesaplandı. Bu indeks ile tüm nedenlere bağlı mortalite gelişimi arasında ilişki olup olmadığı araştırıldı. Bulgular: Grup 1 olarak değerlendirilen NSTEMI grubu SII indeks ortancası Grup II’ye göre anlamlı düzeyde yüksek bulundu (p<0.001). Mortalite gözlenen gruba ait nötrofil ve SII indeksi değerleri ortalaması, sağkalım grubuna göre istatistiksel olarak anlamlı derecede yüksek bulundu (sırasıyla p=0.002 ve p=0.019). Çok yönlü lojistik regresyon sonucunda, NSTEMI varlığı yaş (odds ratio [OR]: 9.891; 95% CI: 2.096-46.671, p<0.001) ve SII indeksinin (odds ratio [OR]: 1.001; 95% CI: 1.000-1001, p=0.039) tüm nedenlere bağlı mortaliteyi bağımsız olarak öngördüğü saptandı. NSTEMI grubunda SII indeksi 609.98 değerinden yüksek olguların sağkalım beklentisi 18 ay için %68.1, SII indeksi 609.98 değerinden düşük olgular için ise %79.3 olarak hesaplandı ancak fark istatistiksel olarak anlamlı bulunmadı (p=0.426). Sonuç: SII, NSTEMI hasta grubunda mortaliteyi ön görmede faydalı bir indeks değildir.
- 23 September 2023
- Published by Medical Journal of Suleyman Demirel University in SDÜ Tıp Fakültesi Dergisi
- Vol. 30 (3) , 388-395
Open AccessST SEGMENT YÜKSELMESİZ MİYOKART ENFARKTÜS HASTALARINDA SİSTEMİK İMMÜN ENFLAMASYON İNDEKSİ VE MORTALİTE İLİŞKİSİ
Aim of the study Acute coronary syndrome (ACS) is a disease associated with high mortality and morbidity. It is essential to identify high-risk patients during hospitalization and to implement early revascularization strategies if necessary. There is a clear need for a simple, effective and cost-effective index for rapid identification of these patients in clinical practice. The aim of this study was to investigate the clinical significance of the systemic immune inflammation index (SII) in non-ST-segment elevation myocardial infarction (NSTEMI), a subgroup of ACS, and to evaluate its association with mortality. Materials and methods Patients who underwent coronary angiography at the Coronary Angiography Unit of Aydın Adnan Menderes University Faculty of Medicine Research and Training Hospital between January and December 2022 were retrospectively reviewed. Individuals with a diagnosis of NSTEMI were included as group I, and individuals with normal coronary arteries during coronary angiography were included as group II (control group). Clinical variables and calculated SII values of the groups were recorded. The role of SII in predicting all-cause mortality and its effect on expected survival were evaluated. Results The median value of the SII index was significantly higher in the NSTEMI group (group I) than in the control group (group II) (p<0.001). The mean neutrophil and SII index values of the mortality group were significantly higher than those of the survival group (p=0.002 and p=0.019, respectively). Multivariate logistic regression showed that the presence of NSTEMI (odds ratio [OR]: 9.891; 95% CI: 2.096-46.671, p609.98 and 79.3% for group I patients with SII <609.98, but the difference was not statistically significant (p=0.426). Conclusion Although the SII index has a role in predicting all-cause mortality in patients with NSTEMI, it is not useful in predicting survival. Amaç: AKS mortalitesi ve morbiditesi yüksek bir sendromdur. Yüksek riskli hastaların hastane yatışı esnasında belirlenmesi ve gerekli durumlarda erken revaskülarizasyon stratejilerinin uygulanması hastalarda hayati önem arz etmektedir. Klinik pratikte bu hastaların hızlıca belirlenmesine yönelik basit, etkili, maliyeti ucuz bir indeks ihtiyacı olduğu aşikardır. Tüm bu nedenlerden dolayı bu çalışmada tarafımızca SII’nın, AKS alt grubu olan NSTEMI geçiren hastalarda mortaliteyi ön görmedeki yerinin araştırılması amaçlanmıştır. Gereç ve Yöntem: 01.01.2022-31.12.2022 tarihleri arasından Aydın Adnan Menderes Üniversitesi Tıp Fakültesi Uygulama ve Araştırma Hastanesi koroner anjiyografi ünitesinde koroner anjiyografi işlemi uygulanan hastalar geçmişe dönük olarak tarandı. St segment yükselmesiz miyokart enfarktüsü geçiren hastalarda ve normal koroner arterler saptanan hastalarda SII [(nötrofil x platelet) / lenfosit] hesaplandı. Bu indeks ile tüm nedenlere bağlı mortalite gelişimi arasında ilişki olup olmadığı araştırıldı. Bulgular: Grup 1 olarak değerlendirilen NSTEMI grubu SII indeks ortancası Grup II’ye göre anlamlı düzeyde yüksek bulundu (p<0.001). Mortalite gözlenen gruba ait nötrofil ve SII indeksi değerleri ortalaması, sağkalım grubuna göre istatistiksel olarak anlamlı derecede yüksek bulundu (sırasıyla p=0.002 ve p=0.019). Çok yönlü lojistik regresyon sonucunda, NSTEMI varlığı yaş (odds ratio [OR]: 9.891; 95% CI: 2.096-46.671, p<0.001) ve SII indeksinin (odds ratio [OR]: 1.001; 95% CI: 1.000-1001, p=0.039) tüm nedenlere bağlı mortaliteyi bağımsız olarak öngördüğü saptandı. NSTEMI grubunda SII indeksi 609.98 değerinden yüksek olguların sağkalım beklentisi 18 ay için %68.1, SII indeksi 609.98 değerinden düşük olgular için ise %79.3 olarak hesaplandı ancak fark istatistiksel olarak anlamlı bulunmadı (p=0.426). Sonuç: SII, NSTEMI hasta grubunda mortaliteyi ön görmede faydalı bir indeks değildir.
- Open Access
- 28 March 2023
- Published by Turkish Journal of Health Science and Life in Turkish Journal of Health Science and Life
- Vol. 6 (1) , 16-22
Old complication, new marker: the relationship between the systemic immune-inflammation index and post-pericardiotomy syndrome.
Background: Post-pericardiotomy syndrome (PPS) is a common complication after cardiovascular surgery. Post-operative hospitalizations are prolonged due to PPS and mortality is increased due to pericardial effusion leading to cardiac tamponade. Studies have shown that inflammation plays a role in etiology. Objectives: The systemic immune-inflammation index (SII) is a new non-invasive marker that has been shown to be effective in predicting inflammatory diseases. In our study, we aimed to investigate the association between the development of PPS and SII in patients undergoing open-heart surgery Methods: Patients who underwent elective open-heart surgery at our institution between 2017 and 2022 were retrospectively studied. Patients who developed PPS and patients who did not develop PPS were included as two different groups in the study. We investigated whether there was a significant difference between the two groups in terms of SII. Results: A total of 228 patients were enrolled in the study, 132 in the patient group and 96 in the control group. The mean age was 63.48 years in the patient group and 65.09 years in the control group and no statistically significant difference was found (p 0.34). There were also no significant differences between the two groups in terms of gender (p 0.47), hypertension (p 0.22), hyperlipidemia (p 0.66), coronary artery disease (p 0.76), diabetes (p 0.023), smoking (p 0.35), and chronic obstructive pulmonary disease (p 0.49). The median value for SII was 568.91 (530.17) in the patient group and 634.79 (613.23) in the control group, and no significant difference was found between the groups (p 0.208). Statistically significant differences were found in hemoglobin (p 0.03), hematocrit (p 0.02), and glucose (p 0.018) values between both groups. Conclusion: The SII is not a useful parameter for predicting post-pericardiotomy syndrome. Comprehensive studies with larger patient populations including subgroup analyzes are needed in this regard.
- 28 March 2023
- Published by Turkish Journal of Health Science and Life in Turkish Journal of Health Science and Life
- Vol. 6 (1) , 16-22
Open AccessOld complication, new marker: the relationship between the systemic immune-inflammation index and post-pericardiotomy syndrome.
Background: Post-pericardiotomy syndrome (PPS) is a common complication after cardiovascular surgery. Post-operative hospitalizations are prolonged due to PPS and mortality is increased due to pericardial effusion leading to cardiac tamponade. Studies have shown that inflammation plays a role in etiology. Objectives: The systemic immune-inflammation index (SII) is a new non-invasive marker that has been shown to be effective in predicting inflammatory diseases. In our study, we aimed to investigate the association between the development of PPS and SII in patients undergoing open-heart surgery Methods: Patients who underwent elective open-heart surgery at our institution between 2017 and 2022 were retrospectively studied. Patients who developed PPS and patients who did not develop PPS were included as two different groups in the study. We investigated whether there was a significant difference between the two groups in terms of SII. Results: A total of 228 patients were enrolled in the study, 132 in the patient group and 96 in the control group. The mean age was 63.48 years in the patient group and 65.09 years in the control group and no statistically significant difference was found (p 0.34). There were also no significant differences between the two groups in terms of gender (p 0.47), hypertension (p 0.22), hyperlipidemia (p 0.66), coronary artery disease (p 0.76), diabetes (p 0.023), smoking (p 0.35), and chronic obstructive pulmonary disease (p 0.49). The median value for SII was 568.91 (530.17) in the patient group and 634.79 (613.23) in the control group, and no significant difference was found between the groups (p 0.208). Statistically significant differences were found in hemoglobin (p 0.03), hematocrit (p 0.02), and glucose (p 0.018) values between both groups. Conclusion: The SII is not a useful parameter for predicting post-pericardiotomy syndrome. Comprehensive studies with larger patient populations including subgroup analyzes are needed in this regard.
- Open Access
- 19 January 2023
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 38 (3) , 601-603
Correction to: Prevalence and Associated Factors of Inappropriate Dosing of Direct Oral Anticoagulants In Patients With Atrial Fibrillation: The ANATOLIA-AF Study
- 19 January 2023
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 38 (3) , 601-603
Open AccessCorrection to: Prevalence and Associated Factors of Inappropriate Dosing of Direct Oral Anticoagulants In Patients With Atrial Fibrillation: The ANATOLIA-AF Study
- Open Access
- 30 December 2022
- Published by Celal Bayar Universitesi Saglık Bilimleri Enstitusu Dergisi in Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi
- Vol. 9 (4) , 473-479
Merkezimizde Sol Ana Koroner Stent İmplantasyonu Uygulanan Hastaların Major Advers Kardiyak Olaylar Açısından İncelenmesi
Giriş ve Amaç: Literatürde yer alan birçok çalışmaya rağmen sol ana koroner arterde kritik darlık saptanan hastaların tedavisinde kesin olarak varılan bir karar bulunmamaktadır. Merkezimizde son beş yıl içerisinde sol ana koroner arter stent implantasyonu yapılan hastaları retrospektif olarak tarayarak koroner arter bypass greft uygulanan hastalar ile kıyaslayıp kendi merkezimizin sonuçlarını paylaşmayı hedefledik. Gereç ve Yöntemler: Koroner arter hastalığı şüphesiyle çeşitli testler sonucunda invaziv koroner anjiyografi uygulanıp sol ana koroner arter kritik darlığı nedeniyle stent implantasyonu (31 hasta) ve ana koroner darlığı ya da üç damar hastalığı nedeniyle bypass kararı verilen (34 hasta) hastalar çalışmaya dahil edildi. Ölüm, inme, miyokart enfarktüsü, tekrarlayan revaskülarizasyon açısından hastalar kıyaslandı. Bulgular: Perkutan koroner girişim grubunda ortalama yaş 68,77±11,46, koroner arter bypass greft grubunda ise 72,82±8,81 olarak izlenmişken p değeri 0,110 olarak saptanmıştır. İki grubun demografik verileri benzer olup gruplar arasında anlamlı fark saptanmamıştır. İki grup arasında kalsiyum kanal blokörü (p 0.049) ve klopidogrel (p 0.001) kullanımı açısından istatistiki anlamlı fark saptanmıştır. Gruplar arasında inme (P 0,981), tekrarlayan revaskülarizasyon ihtiyacı (0,614), ölüm (P 0,21) ve miyokart enfarktüsü (0,071) açısından istatistiki açıdan anlamlı bir fark gözlenmemiştir. Sonuç: Sol ana koroner arter lezyonu olan hastalarda perkutan koroner girişim ve koroner arter bypass greft uygulanmasında inme, tekrarlan revaskülarizasyon, ölüm ve miyokart enfarktüsü açısından fark yoktur.
- 30 December 2022
- Published by Celal Bayar Universitesi Saglık Bilimleri Enstitusu Dergisi in Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi
- Vol. 9 (4) , 473-479
Open AccessMerkezimizde Sol Ana Koroner Stent İmplantasyonu Uygulanan Hastaların Major Advers Kardiyak Olaylar Açısından İncelenmesi
Giriş ve Amaç: Literatürde yer alan birçok çalışmaya rağmen sol ana koroner arterde kritik darlık saptanan hastaların tedavisinde kesin olarak varılan bir karar bulunmamaktadır. Merkezimizde son beş yıl içerisinde sol ana koroner arter stent implantasyonu yapılan hastaları retrospektif olarak tarayarak koroner arter bypass greft uygulanan hastalar ile kıyaslayıp kendi merkezimizin sonuçlarını paylaşmayı hedefledik. Gereç ve Yöntemler: Koroner arter hastalığı şüphesiyle çeşitli testler sonucunda invaziv koroner anjiyografi uygulanıp sol ana koroner arter kritik darlığı nedeniyle stent implantasyonu (31 hasta) ve ana koroner darlığı ya da üç damar hastalığı nedeniyle bypass kararı verilen (34 hasta) hastalar çalışmaya dahil edildi. Ölüm, inme, miyokart enfarktüsü, tekrarlayan revaskülarizasyon açısından hastalar kıyaslandı. Bulgular: Perkutan koroner girişim grubunda ortalama yaş 68,77±11,46, koroner arter bypass greft grubunda ise 72,82±8,81 olarak izlenmişken p değeri 0,110 olarak saptanmıştır. İki grubun demografik verileri benzer olup gruplar arasında anlamlı fark saptanmamıştır. İki grup arasında kalsiyum kanal blokörü (p 0.049) ve klopidogrel (p 0.001) kullanımı açısından istatistiki anlamlı fark saptanmıştır. Gruplar arasında inme (P 0,981), tekrarlayan revaskülarizasyon ihtiyacı (0,614), ölüm (P 0,21) ve miyokart enfarktüsü (0,071) açısından istatistiki açıdan anlamlı bir fark gözlenmemiştir. Sonuç: Sol ana koroner arter lezyonu olan hastalarda perkutan koroner girişim ve koroner arter bypass greft uygulanmasında inme, tekrarlan revaskülarizasyon, ölüm ve miyokart enfarktüsü açısından fark yoktur.
- 17 December 2022
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 38 (3) , 581-599
PrevAleNce and Associated factors of inappropriaTe dosing of direct Oral anticoaguLants In pAtients with Atrial Fibrillation: the ANATOLIA-AF Study
Purpose Inappropriate dosing of direct oral anticoagulants is associated with an increased risk of stroke, systemic embolism, major bleeding, cardiovascular hospitalization, and death in patients with atrial fibrillation. The main goal of the study was to determine the prevalence and associated factors of inappropriate dosing of direct oral anticoagulants in real-life settings. Methods This study was a multicenter, cross-sectional, observational study that included 2004 patients with atrial fibrillation. The study population was recruited from 41 cardiology outpatient clinics between January and May 2021. The main criteria for inappropriate direct oral anticoagulant dosing were defined according to the recommendations of the European Heart Rhythm Association. Results The median age of the study population was 72 years and 58% were women. Nine-hundred and eighty-seven patients were prescribed rivaroxaban, 658 apixaban, 239 edoxaban, and 120 dabigatran. A total of 498 patients (24.9%) did not receive the appropriate dose of direct oral anticoagulants. In a logistic regression model, advanced age, presence of chronic kidney disease and permanent atrial fibrillation, prescription of reduced doses of direct oral anticoagulants or edoxaban treatment, concomitant use of amiodarone treatment, and non-use of statin treatment were significantly associated with potentially inappropriate dosing of direct oral anticoagulants. Conclusion The study demonstrated that the prevalence of inappropriate direct oral anticoagulant dosing according to the European Heart Rhythm Association recommendations was 24.9% in patients with atrial fibrillation. Several demographic and clinical factors were associated with the inappropriate prescription of direct oral anticoagulants.
- 17 December 2022
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 38 (3) , 581-599
PrevAleNce and Associated factors of inappropriaTe dosing of direct Oral anticoaguLants In pAtients with Atrial Fibrillation: the ANATOLIA-AF Study
Purpose Inappropriate dosing of direct oral anticoagulants is associated with an increased risk of stroke, systemic embolism, major bleeding, cardiovascular hospitalization, and death in patients with atrial fibrillation. The main goal of the study was to determine the prevalence and associated factors of inappropriate dosing of direct oral anticoagulants in real-life settings. Methods This study was a multicenter, cross-sectional, observational study that included 2004 patients with atrial fibrillation. The study population was recruited from 41 cardiology outpatient clinics between January and May 2021. The main criteria for inappropriate direct oral anticoagulant dosing were defined according to the recommendations of the European Heart Rhythm Association. Results The median age of the study population was 72 years and 58% were women. Nine-hundred and eighty-seven patients were prescribed rivaroxaban, 658 apixaban, 239 edoxaban, and 120 dabigatran. A total of 498 patients (24.9%) did not receive the appropriate dose of direct oral anticoagulants. In a logistic regression model, advanced age, presence of chronic kidney disease and permanent atrial fibrillation, prescription of reduced doses of direct oral anticoagulants or edoxaban treatment, concomitant use of amiodarone treatment, and non-use of statin treatment were significantly associated with potentially inappropriate dosing of direct oral anticoagulants. Conclusion The study demonstrated that the prevalence of inappropriate direct oral anticoagulant dosing according to the European Heart Rhythm Association recommendations was 24.9% in patients with atrial fibrillation. Several demographic and clinical factors were associated with the inappropriate prescription of direct oral anticoagulants.
- 1 December 2021
- Published by Bayrakol Medical Publishing in Journal of Clinical and Analytical Medicine
- Vol. 12 (12) , 1332-1336
Neutrophil/Lymphocyte ratio can distinguish transudate and exudate pericardial effusions
- 1 December 2021
- Published by Bayrakol Medical Publishing in Journal of Clinical and Analytical Medicine
- Vol. 12 (12) , 1332-1336
Neutrophil/Lymphocyte ratio can distinguish transudate and exudate pericardial effusions
- 31 March 2021
- Published by Turk Spor Bilimleri Dergisi in Türk Spor Bilimleri Dergisi
- Vol. 4 (1) , 33-40
Koronavirüsün Kardiyovasküler Sistem Üzerine Etkileri Işığında Sporcuların Yeniden Sahalara Dönüşünün Değerlendirilmesi
Tüm dünyayı etkisi altına alan ve 2020 yılının en büyük sağlık sorunu haline gelen koronavirüs-19 (Covid-19) enfeksiyonu endotel disfonksiyonuna yol açıp tüm organları etkilemesine rağmen temel etkilerini kalp ve akciğer üzerinde göstermektedir. Profesyonel sporcular risk grubu olarak gösterilmemesine rağmen birçok takım veya sporcular virüs ile enfekte olmuştur. Özellikle sosyal mesafenin korunamadığı sportif faaliyetler sırasındaki bulaş sonrasında semptomatik ve asemptomatik hastalar ortaya çıkmıştır. Günümüzde enfeksiyonu geçiren sporcuların sahalara dönüşü ile ilgili yeni algoritmalara ihtiyaç duyulmaya başlanmıştır. Bu derlemede Covid-19 hastalığı geçiren profesyonel sporcularda virüsün kardiyovasküler sistem üzerine etkilerinin göz önüne alınarak sporcularda sahalara yeniden dönüşünün nasıl olması gerektiğinin tartışılması amaçlanmıştır.
- 31 March 2021
- Published by Turk Spor Bilimleri Dergisi in Türk Spor Bilimleri Dergisi
- Vol. 4 (1) , 33-40
Koronavirüsün Kardiyovasküler Sistem Üzerine Etkileri Işığında Sporcuların Yeniden Sahalara Dönüşünün Değerlendirilmesi
Tüm dünyayı etkisi altına alan ve 2020 yılının en büyük sağlık sorunu haline gelen koronavirüs-19 (Covid-19) enfeksiyonu endotel disfonksiyonuna yol açıp tüm organları etkilemesine rağmen temel etkilerini kalp ve akciğer üzerinde göstermektedir. Profesyonel sporcular risk grubu olarak gösterilmemesine rağmen birçok takım veya sporcular virüs ile enfekte olmuştur. Özellikle sosyal mesafenin korunamadığı sportif faaliyetler sırasındaki bulaş sonrasında semptomatik ve asemptomatik hastalar ortaya çıkmıştır. Günümüzde enfeksiyonu geçiren sporcuların sahalara dönüşü ile ilgili yeni algoritmalara ihtiyaç duyulmaya başlanmıştır. Bu derlemede Covid-19 hastalığı geçiren profesyonel sporcularda virüsün kardiyovasküler sistem üzerine etkilerinin göz önüne alınarak sporcularda sahalara yeniden dönüşünün nasıl olması gerektiğinin tartışılması amaçlanmıştır.
- Open Access
- 30 November 2020
- Published by Turkish Journal of Sports Medicine, Turkish Sports Medicine Association in Turkish Journal of Sports Medicine
- Vol. 56 (1) , 44-47
Correlation of epicardial adipose tissue and skinfold thickness in professional male soccer players
- 30 November 2020
- Published by Turkish Journal of Sports Medicine, Turkish Sports Medicine Association in Turkish Journal of Sports Medicine
- Vol. 56 (1) , 44-47
Open AccessCorrelation of epicardial adipose tissue and skinfold thickness in professional male soccer players